Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer a systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Zhu, Lin ^a   Yu, Hong ^a   Liu, Shi Yuan ^a   Xiao, Xiang Sheng ^a   Dong, Wei Hua ^a   Chen, Yi Nan ^a   Xu, Wei ^b   Zhu, Tong ^c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Shanghai United Imaging Healthcare   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER;

ARTICLE; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TISSUE MICROARRAY; ENZYMOLOGY; FEMALE; LUNG TUMOR; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84928383330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124230     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0 PMID: 23245604
3. Sakashita S, Sakashita M, Sound Tsao M. Genes and pathology of non-small cell lung carcinoma. Semin Oncol. 2014; 41(1):28-39. doi: 10.1053/j.seminoncol.2013.12.008 PMID: 24565579
4. Buyukcelik A, Yalcin B, Utkan G. Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350(19):2008-10; author reply -10. PMID: 15131843
5. Johnson BE, Kelley MJ. Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest. 1993; 103(1 Suppl):1s-3s. PMID: 8380130
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230
7. Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, et al. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010; 28(6):661-9. doi: 10.3109/07357901003735634 PMID: 20394501
8. Peng WJ, Zhang JQ, Wang BX, Pan HF, Lu MM, Wang J. Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clin Chim Acta. 2012; 413(13-14):1121-6. doi: 10.1016/j.cca.2012.06.008 PMID: 22732508
9. Huang AL, Liu SG, Qi WJ, Zhao YF, Li YM, Lei B, et al. TGF-beta1 protein expression in non-small cell lung cancers is correlated with prognosis. Asian Pac J Cancer Prev. 2014; 15(19):8143-7. PMID: 25338997
10. Qian Z, Zhao X, Jiang M, Jia W, Zhang C, Wang Y, et al. Downregulation of cyclophilin A by siRNA diminishes non-small cell lung cancer cell growth and metastasis via the regulation of matrix metallopeptidase 9. BMC Cancer. 2012; 12:442. doi: 10.1186/1471-2407-12-442 PMID: 23031673
11. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem. 1989; 264(29):17374-8. PMID: 2793861
12. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. doi: 10.1016/j.cell.2010.03.015 PMID: 20371345
13. Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, et al. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother. 2012; 35(6):502-12. doi: 10.1097/CJI.0b013e3182619c8e PMID: 22735808
14. Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, et al. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol. 2009; 27(7):1091-9. doi: 10.1200/JCO.2008.16.6991 PMID: 19188679
15. Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol. 1999; 17(6):1802-8. PMID: 10561218
16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMID: 17555582
17. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002; 21(22):3337-51. PMID: 12407676
18. Lv ZQ, Li HG, Zhang W, Jiang SP, Zeng H, Zeng YJ, et al. Prognosis of non-small cell lung cancer and molecular biological factors. J Sun Yat-Sen Univ (Med Sci). 2006(S2:) : 200-202.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. PMID: 12111919
20. Xie ZM. Prediction prognosis ofIstage non-small cell lung cancer Based on the theory of molecular information and chaos. J Sun Yat-Sen Univ; 2007.
21. Zhang LG, Ma Y, Liang YF, Zhang QG. Relaxion between expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and cell apoptosis, suvival in hunam lung caicinoma. Chin J Anat. 2004(01:):31-5.
22. Zhou JH, Wang WX, Wen JF, Cao HQ, Shen M. Expression of MMP-2inverted commas MMP-9inverted commas TIMP-1inverted commas TIMP-2 and clinical pathological significance in non-small cell lung cancer. Pract Prevent Med. 2006(01:):23-6.
23. Iniesta P, Moran A, De Juan C, Gomez A, Hernando F, Garcia-Aranda C, et al. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep. 2007; 17(1):217-23. PMID: 17143501
24. Lim BJ, Jung SS, Choi SY, Lee CS. Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol Med Rep. 2010; 3(1):43-9. doi: 10.3892/mmr-00000216 PMID: 21472198
25. Kumaki F, Matsui K, Kawai T, Ozeki Y, Yu ZX, Ferrans VJ, et al. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol. 2001; 159(6):2125-35. PMID: 11733363
26. Yang DY, Ding CM, Sun ZX, Jing PY, Wang P. Relationship between MMP-2 as well as TIMP-2 and the invation metastasis of non-small cell lung carcinoma. Foreign Med Sci: Respir System. 2005(06:):407-9.
27. Cao JW. Expression and clinical significance of MMP-9 and its inhibitors TIMP-1, TIMP-2 in non-small cell lung cancer. J Guangxi Med Univ; 2010.
28. Li HG, Dong SK, Sheng XM, Zeng yj. Expression of MMP-2 and TIMP-2 in lung carcinoma and its metastasis and prognosis. Chin J Clin Oncol. 2001; 28(1):31-3.
29. Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T, Maehara Y. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surg Today. 2004; 34(11):896-901. PMID: 15526122
30. Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?Ann Oncol. 2010; 21 Suppl 7:vii196-8. doi: 10.1093/annonc/mdq376 PMID: 20943614
31. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012; 76(2):138-43. doi: 10.1016/j.lungcan.2011.11.012 PMID: 22153832
32. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009; 36(3):446-53. doi: 10.1016/j.ejcts.2009.03.063 PMID: 19464919
33. Davies KJ. The Complex Interaction of Matrix Metalloproteinases in the Migration of Cancer Cells through Breast Tissue Stroma. Int J Breast Cancer. 2014; 2014:839094. doi: 10.1155/2014/839094 PMID: 24800085
34. Xue P, Zhao Y, Liu Y, Yuan Q, Xiong C, Ruan J. A novel compound RY10-4 induces apoptosis and inhibits invasion via inhibiting STAT3 through ERK-, p38-dependent pathways in human lung adenocarcinoma A549 cells. Chem Biol Interact. 2014; 209:25-34. doi: 10.1016/j.cbi.2013.11.014 PMID: 24300195
35. Wu KC, Yang ST, Hsia TC, Yang JS, Chiou SM, Lu CC, et al. Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells. Anticancer Res. 2012; 32(11):4833-42. PMID: 23155249
36. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res. 2000; 20(2b):1311-6. PMID: 10810441
37. Ma J, Wang J, Fan W, Pu X, Zhang D, Fan C, et al. Upregulated TIMP-1 correlates with poor prognosis of laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7(1):246-54. PMID: 24427345
38. Wu DW, Tsai LH, Chen PM, Lee MC, Wang L, Chen CY, et al. Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer. Am J Pathol. 2012; 181(5):1796-806. doi: 10.1016/j.ajpath.2012.07.032 PMID: 22982189
39. Giedl J, Hohenberger W, Meister R. The pTNM classification of carcinomas of the lung, and its prognostic significance. Thorac Cardiovasc Surg. 1983; 31(2):71-5. PMID: 6190254
40. Miyake H, Nishikawa M, Tei H, Furukawa J, Harada K, Fujisawa M. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib. Urol Oncol. 2014; 32(5):584-8. doi: 10.1016/j.urolonc.2014.01.016 PMID: 24680659
41. Sela-Passwell N, Kikkeri R, Dym O, Rozenberg H, Margalit R, Arad-Yellin R, et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med. 2012; 18(1):143-7. doi: 10.1038/nm.2582 PMID: 22198278